Myotonic dystrophy type 2
MONDO:0011266Myotonic dystrophy type 2 (MD2), also known as proximal myotonic myopathy, is a very rare genetic multi-system disorder of late childhood or adult-onset characterized by mild myotonia, muscle weakness, and rarely cardiac conduction disorders.
Also known as: CNBP myotonic dystrophy, myotonic dystrophy caused by mutation in CNBP, myotonic dystrophy type 2, proximal myotonic dystrophy, proximal myotonic myopathy, ricker disease, ricker syndrome, DM2
16 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Hope for myotonic dystrophy: new drug shows promise in easing muscle stiffness Long-Term
Symptom relief ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of a drug called mexiletine PR for people with myotonic dystrophy types 1 and 2. The drug is taken once daily as a liquid to help reduce muscle stiffness (myotonia). The study includes 176 adults and teens who have alre…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Brain scans aim to unlock mysteries of muscle disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how myotonic dystrophy types 1 and 2 affect the brain. About 100 adults aged 30-65 will have MRI scans, thinking and movement tests, and blood draws. Some will also have a spinal tap. The goal is to find brain changes that could be used as markers in future tr…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC